Insider Selling: Nektar Therapeutics (NKTR) CEO Sells 33,333 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 33,333 shares of the stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $32.93, for a total value of $1,097,655.69. Following the completion of the transaction, the chief executive officer now owns 328,659 shares of the company’s stock, valued at $10,822,740.87. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

NASDAQ:NKTR traded up $0.99 during trading hours on Friday, hitting $34.06. 60,192 shares of the company were exchanged, compared to its average volume of 1,734,829. Nektar Therapeutics has a one year low of $29.22 and a one year high of $92.17. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21. The firm has a market cap of $5.83 billion, a P/E ratio of 9.01 and a beta of 2.96.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.03. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. The firm had revenue of $28.22 million during the quarter, compared to analyst estimates of $25.45 million. During the same period last year, the company posted ($0.60) EPS. As a group, equities research analysts expect that Nektar Therapeutics will post -3.14 EPS for the current year.

Hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. raised its position in shares of Nektar Therapeutics by 150.2% in the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 479 shares in the last quarter. Quantamental Technologies LLC bought a new position in shares of Nektar Therapeutics in the 1st quarter worth about $27,000. CSat Investment Advisory L.P. raised its position in shares of Nektar Therapeutics by 279.2% in the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 790 shares in the last quarter. Laurel Wealth Advisors LLC bought a new position in shares of Nektar Therapeutics in the 4th quarter worth about $39,000. Finally, Sandy Spring Bank bought a new position in shares of Nektar Therapeutics in the 4th quarter worth about $59,000. 91.33% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts have recently commented on NKTR shares. Mizuho reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research report on Tuesday, February 19th. Piper Jaffray Companies set a $100.00 target price on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 1st. TheStreet raised Nektar Therapeutics from a “d+” rating to a “c” rating in a research report on Thursday, February 28th. HC Wainwright reaffirmed a “hold” rating and set a $47.00 target price on shares of Nektar Therapeutics in a research report on Tuesday, February 19th. Finally, ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $69.73.

WARNING: This report was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.thestockobserver.com/2019/05/24/insider-selling-nektar-therapeutics-nktr-ceo-sells-33333-shares-of-stock.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Story: Treasury Bonds

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.